From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development

• URL: http://arxiv.org/abs/2412.09378v2
• Date: Thu, 19 Dec 2024 15:14:18 GMT
• Title: From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development
• Abstract summary: Clinical trials are an indispensable part of the drug development process.<n>The paper addresses the major challenges encountered in clinical trials, such as ethical issues, subject recruitment difficulties, diversity and representativeness concerns.<n>The article looks forward to the future of clinical trials, particularly the impact of emerging therapies such as gene therapy and immunotherapy on trial design.
• Score: 16.983261704407784
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Clinical trials are an indispensable part of the drug development process, bridging the gap between basic research and clinical application. During the development of new drugs, clinical trials are used not only to evaluate the safety and efficacy of the drug but also to explore its dosage, treatment regimens, and potential side effects. This review discusses the various stages of clinical trials, including Phase I (safety assessment), Phase II (preliminary efficacy evaluation), Phase III (large-scale validation), and Phase IV (post-marketing surveillance), highlighting the characteristics of each phase and their interrelationships. Additionally, the paper addresses the major challenges encountered in clinical trials, such as ethical issues, subject recruitment difficulties, diversity and representativeness concerns, and proposes strategies for overcoming these challenges. With the advancement of technology, innovative technologies such as artificial intelligence, big data, and digitalization are gradually transforming clinical trial design and implementation, improving trial efficiency and data quality. The article also looks forward to the future of clinical trials, particularly the impact of emerging therapies such as gene therapy and immunotherapy on trial design, as well as the importance of regulatory reforms and global collaboration. In conclusion, the core role of clinical trials in drug development will continue to drive the progress of innovative drug development and clinical treatment.

Related papers

• Simulating Viva Voce Examinations to Evaluate Clinical Reasoning in Large Language Models [51.91760712805404]
  We introduce VivaBench, a benchmark for evaluating sequential clinical reasoning in large language models (LLMs)<n>Our dataset consists of 1762 physician-curated clinical vignettes structured as interactive scenarios that simulate a (oral) examination in medical training.<n>Our analysis identified several failure modes that mirror common cognitive errors in clinical practice.
  arXiv  Detail & Related papers  (2025-10-11T16:24:35Z)
• Medical Reasoning in the Era of LLMs: A Systematic Review of Enhancement Techniques and Applications [59.721265428780946]
  Large Language Models (LLMs) in medicine have enabled impressive capabilities, yet a critical gap remains in their ability to perform systematic, transparent, and verifiable reasoning.<n>This paper provides the first systematic review of this emerging field.<n>We propose a taxonomy of reasoning enhancement techniques, categorized into training-time strategies and test-time mechanisms.
  arXiv  Detail & Related papers  (2025-08-01T14:41:31Z)
• SECRET: Semi-supervised Clinical Trial Document Similarity Search [22.008566744843353]
  We present a novel method to identify similar historical trials by summarizing clinical trial protocols and searching for similar trials based on a query trial's protocol.<n>Our approach significantly outperforms all baselines, achieving up to a 78% improvement in recall@1 and a 53% improvement in precision@1 over the best baseline.
  arXiv  Detail & Related papers  (2025-05-16T01:34:16Z)
• Towards Regulatory-Confirmed Adaptive Clinical Trials: Machine Learning Opportunities and Solutions [59.28853595868749]
  We introduce two new objectives for future clinical trials that integrate regulatory constraints and treatment policy value for both the entire population and under-served populations. We formulate Randomize First Augment Next (RFAN), a new framework for designing Phase III clinical trials. Our framework consists of a standard randomized component followed by an adaptive one, jointly meant to efficiently and safely acquire and assign patients into treatment arms during the trial.
  arXiv  Detail & Related papers  (2025-03-12T10:17:54Z)
• Clinical Evaluation of Medical Image Synthesis: A Case Study in Wireless Capsule Endoscopy [63.39037092484374]
  This study focuses on the clinical evaluation of medical Synthetic Data Generation using Artificial Intelligence (AI) models. The paper contributes by a) presenting a protocol for the systematic evaluation of synthetic images by medical experts and b) applying it to assess TIDE-II, a novel variational autoencoder-based model for high-resolution WCE image synthesis. The results show that TIDE-II generates clinically relevant WCE images, helping to address data scarcity and enhance diagnostic tools.
  arXiv  Detail & Related papers  (2024-10-31T19:48:50Z)
• TrialSynth: Generation of Synthetic Sequential Clinical Trial Data [21.799655542003677]
  Variational Autoencoder (VAE) designed to address challenges of generating synthetic time-sequence clinical trial data. Our experiments demonstrate that Trial Synth surpasses the performance of other comparable methods.
  arXiv  Detail & Related papers  (2024-09-11T08:20:30Z)
• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• TrialBench: Multi-Modal Artificial Intelligence-Ready Clinical Trial Datasets [57.067409211231244]
  This paper presents meticulously curated AIready datasets covering multi-modal data (e.g., drug molecule, disease code, text, categorical/numerical features) and 8 crucial prediction challenges in clinical trial design. We provide basic validation methods for each task to ensure the datasets' usability and reliability. We anticipate that the availability of such open-access datasets will catalyze the development of advanced AI approaches for clinical trial design.
  arXiv  Detail & Related papers  (2024-06-30T09:13:10Z)
• Language Interaction Network for Clinical Trial Approval Estimation [37.60098683485169]
  We introduce the Language Interaction Network (LINT), a novel approach that predicts trial outcomes using only the free-text descriptions of the trials. We have rigorously tested LINT across three phases of clinical trials, where it achieved ROC-AUC scores of 0.770, 0.740, and 0.748.
  arXiv  Detail & Related papers  (2024-04-26T14:50:59Z)
• TrialDura: Hierarchical Attention Transformer for Interpretable Clinical Trial Duration Prediction [19.084936647082632]
  We propose TrialDura, a machine learning-based method that estimates the duration of clinical trials using multimodal data. We encode them into Bio-BERT embeddings specifically tuned for biomedical contexts to provide a deeper and more relevant semantic understanding. Our proposed model demonstrated superior performance with a mean absolute error (MAE) of 1.04 years and a root mean square error (RMSE) of 1.39 years compared to the other models.
  arXiv  Detail & Related papers  (2024-04-20T02:12:59Z)
• Towards quantum computing for clinical trial design and optimization: A perspective on new opportunities and challenges [0.250217476520467]
  This paper examines the current challenges faced in clinical trial design and optimization. The focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification.
  arXiv  Detail & Related papers  (2024-04-19T18:00:25Z)
• SPOT: Sequential Predictive Modeling of Clinical Trial Outcome with Meta-Learning [67.8195828626489]
  Clinical trials are essential to drug development but time-consuming, costly, and prone to failure. We propose Sequential Predictive mOdeling of clinical Trial outcome (SPOT) that first identifies trial topics to cluster the multi-sourced trial data into relevant trial topics. With the consideration of each trial sequence as a task, it uses a meta-learning strategy to achieve a point where the model can rapidly adapt to new tasks with minimal updates.
  arXiv  Detail & Related papers  (2023-04-07T23:04:27Z)
• Contextual Constrained Learning for Dose-Finding Clinical Trials [102.8283665750281]
  C3T-Budget is a contextual constrained clinical trial algorithm for dose-finding under both budget and safety constraints. It recruits patients with consideration of the remaining budget, the remaining time, and the characteristics of each group.
  arXiv  Detail & Related papers  (2020-01-08T11:46:48Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.